Developmental Funds

发展基金：摘要 癌症中心支持助学金(CCSG)发展基金对完成加州大学的使命至关重要 佛罗里达健康癌症中心(UFHCC)。发展基金促进创新研究和战略 招聘工作与中心的战略举措保持一致。自2016年以来，UFCC在全球范围内开展了合作 佛罗里达大学在内部和外部招募了58名UFCC新成员(UF新成员45名)， 其中39人(67%)是早期调查员，26人(45%)是女性，10人(17%)代表性不足 少数族裔。在为UFCC提供成员的学院中，有8所学院招募了教师。在这些新兵中， 20个是肿瘤发生机制的成员，19个是癌症治疗和宿主反应的成员， 19个是癌症控制和人口科学，显示出在各个项目中的均匀分布。UFCC 承诺为所有招聘提供2990万美元的初创支持，迄今已支出1440万美元。这些新的 UFCC成员已经在合作方面为该中心做出了重大贡献 计划性和多机构研究、出版物和干预性临床试验。重要的是，因为 加入UF，这些新成员获得了56个新的同行评审的校外赠款，总额为3900万美元(直接 成本)，其中1480万美元(约38%)来自NCI。包括转移赠款在内的全部外部资金，归因于 给这些新人的是5240万美元(直接成本)，其中2420万美元(46%)由NCI奖励。的投资回报 UFCC迄今的招聘费用相对于以下所有外部同行审查资金(直接成本) 招聘人数：3.6：1。自2016年以来，UFCC试点和探索性研究提案共收到183份提案 审查，33%的人批准了资助。2016至2020年期间授予的项目成果， 已经过去了足够的时间来评估影响(300万美元的试点资金)，包括159份出版物和2000万美元(直接 所有奖励年度的费用)在新的外部同行审查资金中，投资回报率约为6.7：1。 2016年，发展基金帮助扩大了UFCC的资金组合。带着新的 在招募人员方面，与癌症相关的资金总额从2016年的2100万美元增加到2021年的3260万美元(增加了55%)， NCI资金从960万美元增加到1320万美元(增长37%)。公司的整体研究效率 UFCC从2016年的369篇增加到2021年的641篇(增长1.7倍)。出版的出版物数量 Impact≥10从2016年的59个增加到2021年的95个。自2016年以来，发展基金也为招聘提供了支持 18名研发出新型介入性IITs的成员。2016年，机构间投资信托基金应计项目占 参与者参加了试验(23%的治疗收益)。2021年，应计税项占注册人数的91% (59%的治疗)。干预试验应计项目从2016年的515项增加到2021年的1748项(增长3.4倍)。 治疗应计项目从2016年的138项增加到2021年的299项(增长2.2倍)。将使用开发资金 用于试点拨款，以鼓励与集水区相关的癌症的创新跨学科科学；以及 在3个研究项目中招募高素质和多样化的新成员。

DEVELOPMENTAL FUNDS: ABSTRACT Cancer Center Support Grant (CCSG) Developmental Funds are critical to fulfill the mission of the University of Florida Health Cancer Center (UFHCC). Developmental Funds foster innovative research and strategic recruitment aligned with the Center's strategic initiatives. Since 2016, the UFHCC has collaborated across the University of Florida in the internal and external recruitment of 58 new UFHCC members (45 new to UF), of which 39 (67%) are early-stage investigators (ESIs), 26 (45%) are women, and 10 (17%) are underrepresented minorities. Faculty were recruited into 8 of the colleges that contribute members to the UFHCC. Of these recruits, 20 are members of Mechanisms of Oncogenesis, 19 are members of Cancer Therapeutics and Host Response, and 19 are in Cancer Control and Population Sciences, showing even distribution across the programs. UFHCC committed a total of $29.9M in start-up support for all recruitment, with $14.4M expended to date. These new UFHCC members have already made significant contributions to the center in terms of collaborative programmatic and multi-institutional research, publications, and interventional clinical trials. Importantly, since joining UF, these new members have obtained 56 new peer-reviewed extramural grants totaling $39M (direct costs), of which $14.8M (~38%) is from NCI. The total extramural funding, including transferred grants, attributed to these recruits is $52.4M (direct costs), with $24.2M (46%) awarded by the NCI. The return on investment on UFHCC recruitment expenses to date relative to all extramural peer-reviewed funding (direct costs) attributed to recruits is >3.6:1. Since 2016, the UFHCC Pilot and Exploratory Study Proposals received 183 proposals for review, with 33% approved for funding. Outcomes of projects awarded between 2016 and 2020, for which enough time had passed to assess impact ($3M of pilot funding), included 159 publications and $20M (direct costs, for all award years) in new extramural peer-reviewed funding, a return on investment ratio of ~6.7:1. Since 2016, Developmental Funds have assisted in the expansion of the UFHCC funding portfolio. With the new recruits, total cancer-relevant funding increased from $21M in 2016 to $32.6M in 2021 (up 55%) direct costs, NCI funding increasing from $9.6M to $13.2M (up 37%) direct costs. The overall research productivity of the UFHCC increased from 369 publications in 2016 to 641 in 2021 (up 1.7-fold). The number of publications with impact ≥10 went from 59 in 2016 to 95 in 2021. Since 2016, Developmental Funds also supported the recruitment of 18 members who developed novel interventional IITs. In 2016, accruals to IITs accounted for 70% of participants enrolled in trials (23% of treatment accruals). In 2021, IIT accruals accounted for 91% of enrollments (59% of treatment). Interventional trial accruals increased from 515 in 2016 to 1,748 in 2021 (up 3.4-fold). Treatment accruals increased from 138 in 2016 to 299 in 2021 (up 2.2-fold). Developmental funds will be used for pilot grants to encourage innovative transdisciplinary science on cancers relevant to the catchment area, and recruitment of highly qualified and diverse new members across the 3 research programs.